TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06504147: A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant

Sponsor: Oncoinvent Solutions AS · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 114 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT06504147 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06504147 Rescue Dossier →